Latest News
ASCO and EHA highlights in myeloma and AL amyloidosis
The American Society of Clinical Oncology Annual Meeting (ASCO2020) is the largest and one of the most important congresses for the oncology community. Many myeloma and AL amyloidosis updates were presented at this congress which…
FDA Refusal to File letter for Idecabtagene Vicleucel (ide-cel, bb2121) for the treatment of myeloma patients
Bristol Myers Squibb (BMS) and bluebird bio, Inc have announced that the companies received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for…
MPE webinar on the impact of myeloma and AL amyloidosis in carers. What are the issues and challenges?
Myeloma Patients Europe (MPE) will hold a webinar on the impact of myeloma and AL amyloidosis in carers on Wednesday 20 May 2020 from 18:00 – 19:00 CET. The webinar will be given by…
MPE webinar on personalised medicines in myeloma and AL amyloidosis
Myeloma Patients Europe (MPE) will hold a webinar on personalised medicines in myeloma and AL amyloidosis on Wednesday 6 May 2020 from 18:00 – 19:00 CET.
New clinical trial to evaluate the myeloma drug selinexor as potential treatment for patients with COVID-19
The pharmaceutical company, Karyopharm Therapeutics has announced plans to initiate a global randomized clinical trial for low dose oral selinexor in hospitalized patients with severe COVID-19 (coronavirus). Selinexor, marketed as XPOVIO®, is currently approved at…
MPE webinar on Minimal Residual Disease (MRD) in myeloma and related diseases
Myeloma Patients Europe (MPE) will hold a webinar on Minimal Residual Disease (MRD) in myeloma and related diseases on Monday 20 April 2020 from 18:00 – 19:00 CET.
How to cope with confinement during the COVID-19 outbreak
The increase in the number of people affected by COVID-19 (coronavirus) has generated great concern, and has forced a number of countries to implement measures in order to stop the spreading of the virus. These…
- MO
- TU
- WE
- TH
- FR
- SA
- SU
- 28
- 29
- 30
- 31
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31